Short answer
Vertex Pharmaceuticals (VRTX) filed its Q2 2025 10-Q quarterly report on Aug 5, 2025 for the quarter ended Jun 30, 2025. Quarterly revenue was $3.0B (up 12.1% year over year) with net income of $1.0B.
Q2 2025 key financials · XBRL
- Revenue
- $3.0B
- +12.1% YoY · +7.0% QoQ
- Net income
- $1.0B
- +128.7% YoY · +59.8% QoQ
- Operating margin
- 38.8%
- EPS (diluted)
- $3.99
- +128.8% YoY · +60.2% QoQ
Source: XBRL data from the Vertex Pharmaceuticals (VRTX) Q2 2025 10-Q on SEC EDGAR. USD.
Vertex Pharmaceuticals Q2 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No new or materially changed risk factors disclosed in quarterly filing versus most recent 10-K
- Regulatory risk: ongoing FDA interactions and accelerated approvals remain critical for clinical trial timelines and product launches
- Operational risk: dependency on successful expansion of CF patient eligibility and reimbursement agreements impacts near-term revenue growth
- Competitive risk: pipeline development and collaborations to address unmet medical needs require timely R&D progress and integration
- Financial risk: exposure to foreign currency fluctuations managed via foreign currency program, impacting cash flow and income forecasts
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Vertex Pharmaceuticals quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.